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26786
Delphi method study in defining surgical site infection following
Mohs surgery
Vijaya T. Daniel, MD, MPH, University of Massachusetts, Department of
Dermatology; Ailish M. Hanley, BS, University of Massachusetts,
Department of Dermatology; Bassel H. Mahmoud, MD, PhD, University of
Massachusetts, Department of Dermatology
Background: Although the Centers for Disease Control and Prevention (CDC) has
defined surgical site infection (SSI) as occurring within 30 days of a procedure and
having certain characteristics, this definition is infrequently used in the dermatologic literature and among dermatologists.
Methods: A Delphi study was conducted among a national panel of 5 Mohs surgeon
experts to assess consensus related to the definition of SSI following Mohs surgery.
Consensus was defined when a scenario was rated as very important or absolutely
essential by $80% of the experts.
Results: Sixty percent of experts were female, 40% had been in practice $21 years,
and 80% were from academic settings. No consensus on SSI was achieved in the
clinical scenario where the surgical site had warmth, swelling, or erythema without
pain or discharge on postoperative day 7. Eighty percent of experts do not require
positive wound cultures to diagnose a SSI. No experts were familiar with the CDC
definition nor had standardized criteria for SSI. One expert noted in an open-ended
question that ‘‘diagnosis of SSI can be challenging...while pain is often the very first
sign of infection.on rare occasion, it is absent.’’
Conclusions: Consensus on the definition of SSI is difficult to reach among Mohs
surgeons, which implies that further refinement of the definition of SSI is needed to
compare patient outcomes in dermatology. Based on the results of this study, we are
currently developing a larger survey to administer to the members of the American
College of Mohs Surgery.
Commercial Disclosure: None identified.
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Analysis of cutaneous T cell lymphoma hospitalizations in the
United States
Ehizogie Edigin, MD, John H. Stroger Jr. Hospital of Cook County;
Precious Obehi Eseaton, MBBS, College of Medicine, University of
Benin
Background: There is paucity of national population studies on cutaneous T cell
lymphoma hospitalizations in the United States (U.S). This study aims to determine
baseline characteristics and the most common reasons for hospitalization of patients
with cutaneous T cell lymphoma (CTL).
Methods: Data were abstracted from the National Inpatient Sample (NIS), the largest
inpatient hospitalization database in the U.S. The NIS was searched for CTL
hospitalizations in 2016 and 2017 using ICD-10 codes ‘‘C840,’’ ‘‘C841,’’ and ‘‘C84A’’
as the principal or secondary diagnosis. CTL hospitalizations included Sezary
syndrome, mycosis fungoides and unspecified CTL.
Results: There were over 71 million discharges included in the combined 2016 and
2017 NIS database. 7,275 hospitalizations had an ICD 10 code for CTL. CTL Patients
were mostly white (63.5%), male (56.4%), mean age of 65.0 years, mean hospital
length of stay was 8.3 days and mean total hospital charges was $87,355. The top 5
reasons for CTL hospitalization by ICD-10 code system-based categories were:
hemato-oncology 1,505 (20.7%), infections 1,390 (19.1%), cardiovascular 795
(10.9%), respiratory 515 (7.1%), and gastrointestinal 400 (5.5%). The top 5 most
common specific principal diagnosis of CTL hospitalizations in descending order of
frequency were sepsis from unspecified organism, admission for antineoplastic
chemotherapy, CTL, acute kidney injury, and pneumonia from unspecified
organism.
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Alopecia areata and risk of cancer varies based on type of
malignancy
Kevin Phan, MD, St. George Dermatology and Skin Cancer Centre;
Saxon D. Smith, FACD, The Dermatology & Skin Cancer Centre,
Gosford, Australia
Introduction: Alopecia areata (AA) is an autoimmune skin disorder characterized by
patchy hair loss, most often on the scalp. Defects in the immune system and various
autoimmune disorders have been shown to be associated with malignancy.
However, the association between AA and cancer is not extensively studied.
Objective: To determine if an association exists between AA and various
malignancies.
Methods: A systematic search of Pubmed, MEDLINE, Embase and the Cochrane
Library was conducted. Case-control or cohort studies that assessed the association
between AA and malignancy were included. DerSimonian and Laird random-effects
models were used to calculate the pooled prevalence and odds ratios.
Results: After systematic search, 8 studies were identified and included for metaanalysis. AA was associated with reduced odds of nonmelanoma skin cancers (OR
0.61, P \.00001) but no association with melanomas. AA was also associated with
reduced risk of gastric cancers (OR 0.70, P ¼ .04), hepatobiliary and pancreatic
cancers (OR 0.83, P ¼ .04), and uterine and cervical cancer (OR 0.92, P ¼.05). AA
was associated with increased risk of prostate cancer (OR 1.26, P \.00001) and
thyroid cancer (OR 1.31, P ¼.008). No significant association was found between AA
and oral, nasopharyngeal/esophageal, breast, colorectal, lung, kidney, connective
tissue, or haematological malignancies, including lymphoma, leukamia, or multiple
myeloma.
Conclusions: The risk of cancer in AA varies according to subtype of malignancy. AA
appears to have decreased risk of a number of cancers by an unclear mechanism,
possibly due to the negative effect of autoimmune diseases on carcinogenesis.
Commercial Disclosure: None identified.
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Introduction: Hidradenitis suppurativa (HS) is often refractory to medical and
surgical interventions. Carbon dioxide (CO2) laser excision has demonstrated
promising results for HS treatment.
Objective: We characterized the efficacy and safety of CO2 laser excision for HS in
smokers and diabetics.

Conclusion: Patients with CTL are most likely to be hospitalized because of
infections and their underlying hemato-oncologic disorders. Infection prevention/control, and more focused hemato-oncology outpatient follow up for their underlying hemato-oncologic disorders are important in reducing the likelihood of
hospitalization.

Methods: On initial data pull, 72 patients were identified. This number was reduced
to 38 patients by including HS patients with all data points at Henry Ford Hospital
who underwent CO2 laser excision between August 2014 to May 2017. Data were
obtained from medical charts including healing and recurrence rates, complications,
smoking status, and history of diabetes mellitus.
Results: The average age of our cohort was 37.5 years and mean BMI was 34.9. In
total, 3 patients had recurrence at a mean of 6 months following the procedure.
Postoperative complications included: infection (n ¼ 2), contracture (n ¼ 2),
dehiscence (n ¼ 2), and paresthesia (n ¼ 1). Patients with dehiscence were not
smokers or diabetics. Twelve patients were smokers, and 26 patients were
nonsmokers. The mean healing time in both smokers and nonsmokers was 6
months. Nine patients had a history of diabetes mellitus (DM), and 29 patients were
not diabetic. The mean healing time was not significantly prolonged in diabetics
compared to nondiabetics and was 7.3 months and 5.4 months, respectively.
Conclusion: Both smokers and nonsmokers demonstrated similar healing time,
recurrence rates, and postoperative complications. Patients with DM had prolonged
healing times when compared to those without DM. Our study identifies important
characteristics that clinicians should consider when assessing HS patients for CO2
laser excision.
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